The estimated Net Worth of Aparna Ahuja is at least $277 mil dollars as of 6 January 2022. Dr Ahuja owns over 61,988 units of T2 Biosystems Inc stock worth over $247,505 and over the last 4 years he sold TTOO stock worth over $29,754.
Dr has made over 2 trades of the T2 Biosystems Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 61,988 units of TTOO stock worth $29,754 on 6 January 2022.
The largest trade he's ever made was exercising 153,664 units of T2 Biosystems Inc stock on 5 January 2022 worth over $353,427. On average, Dr trades about 53,913 units every 0 days since 2021. As of 6 January 2022 he still owns at least 107,611 units of T2 Biosystems Inc stock.
You can see the complete history of Dr Ahuja stock trades at the bottom of the page.
Dr. Aparna Jha Ahuja M.D. is the Chief Medical Officer at T2 Biosystems Inc.
Dr D is 54, he's been the Chief Medical Officer of T2 Biosystems Inc since . There are 12 older and 6 younger executives at T2 Biosystems Inc. The oldest executive at T2 Biosystems Inc is John Cumming, 74, who is the Lead Independent Director.
Aparna's mailing address filed with the SEC is 101, Hartwell Avenue, Lexington, Middlesex County, Massachusetts, 02421, United States.
Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ... y Thomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
T2 Biosystems Inc executives and other stock owners filed with the SEC include: